Related Experiment Video
Updated: Mar 1, 2026

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice
Published on: February 20, 2019
Therapeutic strategies for atherosclerosis and atherothrombosis: Past, present and future
Christian Weber1, Lina Badimon, François Mach
1Dr. Christian Weber or Dr. Emiel van der Vorst, Institute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Pettenkoferstr. 9, 80336 Munich, Germany, Tel.: +49 89 4400 54610, Fax: + 49 89 4400 54352, E-mail: christian.weber@med.uni-muenchen.de or, Emiel.Van_der_Vorst@med.uni-muenchen.de.
Insights
Atherosclerosis and atherothrombosis are major global health threats. This review covers current and emerging anti-inflammatory therapies to reduce residual risk and improve patient outcomes.
Area of Science:
- Cardiovascular Medicine
- Inflammation Research
- Pharmacology
Background:
- Atherosclerosis and atherothrombosis are leading global causes of mortality.
- Understanding has evolved from lipid-driven to a multifactorial inflammatory process.
- This shift necessitates novel anti-inflammatory therapeutic strategies.
Purpose of the Study:
- To provide a historical overview of atherosclerosis and atherothrombosis research.
- To review current state-of-the-art therapies for these conditions.
- To highlight promising future therapeutic strategies and clinical investigations.
Main Methods:
- Literature review of historical data and current research.
- Synopsis of existing therapeutic options for atherosclerosis and atherothrombosis.
- Analysis of ongoing investigations into novel and combination therapies.
Main Results:
- Current therapies address aspects of atherosclerosis and atherothrombosis.
- Significant residual risk persists despite existing treatments.
- Emerging anti-inflammatory and combination therapies show promise.
Conclusions:
- Continued research and clinical trials are crucial for advancing treatment.
- Novel therapeutic combinations aim to further reduce residual cardiovascular risk.
- Future developments promise improved management of atherosclerosis and atherothrombosis.
Abstract:
Even two centuries after they were first described, atherosclerosis and atherothrombosis remain among the leading causes of death worldwide. Over the last decades it has become clear that atherosclerosis is not only a lipid-driven disease but also a multifactorial process largely driven by inflammatory mediators, an insight that has instigated additional research and drug development focussing on anti-inflammatory therapies. In this review, we will provide a brief historical overview, followed by a more general synopsis of the range of currently available state-of-the-art therapies for atherosclerosis and atherothrombosis. Finally, we will highlight some of the promising therapeutic strategies that are currently under intense investigation. We believe that the next years will witness highly interesting developments and clinical trials investigating yet more novel therapies, and at the same time looking into potential combinations of all available therapies. This prospect closes in on the ultimate goal, which is to reduce the residual risk that still persists despite present therapeutic options.
Related Concept Videos
Atherosclerosis III: Management
Atherosclerosis IV: Nursing Management
Coronary Artery Disease V: Interprofessional Care
Peripheral Artery Disease III: Interprofessional Care
Angina IV: Management
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

